Rosetta Genomics Ltd Ord: (NASD: ROSG)
$3.77
0.37 (10.88%)
Volume 981,909
May 20 04:00 PM ET
Zacks Rank: NA 
| |
Overview Quote
Stock Activity
| Day Low - High | 3.70 - 3.98 |
| 52wk Low - High | 3.09 - 23.43 |
| Previous Close | 3.40 |
| Avg. Volume | 297,096 |
| Industry | MED-BIOMED/GENE |
| Market Cap | 34.30 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | -1.82 |
| PE (Forward) | 0.00 |
| Current Year Est. | 0.00 |
| Quarterly Earnings ESP |
NA |
Premium research
Zacks Rank
|
|
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
91 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Key Earnings Data
| PE (Forward) | NA |
| PEG Ratio | NA |
| Current Year Est. | NA |
| Current Quarter Estimate | NA |
| Most Accurate Estimate | NA |
| Earnings ESP |
NA |
| Next Earnings Report Date | NA |
| EPS Last Year | NA |
| Expected Earnings Growth | NA |
Company Description
Rosetta Genomics is a leader in the field of microRNA. The company's integrative research platform combining bioinformatics and state-of-the-art laboratory processes has led to the discovery of hundreds of biologically validated novel human microRNAs. Building on its strong IP position and proprietary platform technologies, Rosetta Genomics is working on the application of these technologies in the development of a full range of microRNA-based diagnostic and therapeutic tools, focusing primarily on cancer and various women's health indications.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Turn Earnings Surprises into quick profits.
Earnings Estimates
| Current Qtr (ND) |
Next Qtr (ND) |
Current Year (ND) |
Next Year (ND) |
|
|---|---|---|---|---|
| Average Estimate | NA | NA | NA | NA |
| Number of Estimates | NA | NA | NA | NA |
| Low Estimate | NA | NA | NA | NA |
| High Estimate | NA | NA | NA | NA |
| Year Ago EPS | NA | NA | NA | NA |
| EPS Growth | NA | NA | NA | NA |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| AETERNA ZENTARS | AEZS | 2.06 | |
|
| ANIKA THERAPEUT | ANIK | 14.39 | |
|
| GENTIUM SPA-ADR | GENT | 8.84 | |
|
| AASTROM BIOSCI | ASTM | 0.59 | |
|
| ACHILLION PHARM | ACHN | 7.55 | |
|
| ADDEX THERA LTD | ADDXF | 6.94 | |
|
| AFFYMAX INC | AFFY | 1.27 | |
|
| ALEXION PHARMA | ALXN | 100.03 | |
|
| ALKERMES INC | ALKS | 31.04 | |
|
| ALNYLAM PHARMA | ALNY | 27.56 | |
|
Sector:Medical>> Industry:MED-BIOMED/GENE
COMPARE TICKER vs. Its Peers
Zacks Commentary
Financials
| EPS TTM | NA |
| Sales | 0 |
| Net Income | NA |
| Price/Earnings | NA |
| Price/Book | 1.11 |
| Price/Cash Flow | NA |
| Price/Sales | NA |
News
Rosetta Genomics Wins Credentialing Deal with Prime Health Services for miRview mets2 - Benzinga
May 20, 2013
Rosetta Genomics Receives Full Settlement Payment from Sanra Laboratories - Benzinga
May 10, 2013
4 Health Care Stocks Under $10 to Watch - TheStreet.com
Apr 2, 2013
Rosetta Genomics Receives 25th U.S. Patent Allowance - Benzinga
Mar 18, 2013
Rosetta Genomics Wins Two Key US Patent Allowances - Benzinga
Feb 14, 2013
5 Stocks Under $10 Ready to Soar Higher - TheStreet.com
Feb 7, 2013
3 Stocks Under $5 Making Big Moves - TheStreet.com
Feb 5, 2013
Morning Market Movers - Benzinga
Jan 9, 2013
Broker Recommendations
| Current ABR | 1.00 |
| ABR (Last Week) | 1.00 |
| # of recs in ABR | 1 |
| Average Target Price | NA |
| Industry Rank by ABR | 91 out of 265 |
| Rank in Industry | NA |
